Skip to main content

Rallybio Corp

For the period ended Dec 31, 2024. Filed Mar 13, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 13, 2025

RLYB$15.76+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders' Equity

COMMON · ADDITIONALPAID-INCAPITAL · ACCUMULATEDDEFICIT · ACCUMULATED OTHERCOMPREHENSIVEGAIN (LOSS) · STOCKHOLDERS'EQUITY
(in thousands, except share amounts) · SHARES · AMOUNT
December 31, 202237,837,369$4$330,208$(160,681)$(214)$169,317
Issuance of common stock from the stock purchase plan79,283—282——282
Issuance of common stock from the stock award plan11,219—————
Forfeiture of restricted common stock(98,306)—————
Share-based compensation expense——10,920——10,920
Net loss———(74,564)—(74,564)
Other comprehensive gain————229229
Balance, December 31, 202337,829,565$4$341,410$(235,245)$15$106,184
Issuance of common stock upon completion of a securities purchase agreement, net of offering costs of $2683,636,363$—$5,137$—$—$5,137
Issuance of common stock from the stock purchase plan60,866—62——62
Issuance of common stock from the stock award plan1,925—————
Forfeiture of restricted common stock(18,556)—————
Share-based compensation expense——7,993——7,993
Net loss———(57,775)—(57,775)
Other comprehensive gain————5353
Balance, December 31, 202441,510,163$4$354,602$(293,020)$68$61,654
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.